Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/49324
DC FieldValueLanguage
dc.contributor.authorHernandez-Trujillo, Y.
dc.contributor.authorRodriguez-Esparragon, F.
dc.contributor.authorMacias-Reyes, A.
dc.contributor.authorCaballero-Hidalgo, A.
dc.contributor.authorRodriguez-Perez, Jose C.
dc.contributor.otherRodriguez-Perez, J.C.
dc.contributor.otherRodriguez-Esparragon, Francisco
dc.date.accessioned2018-11-24T06:16:00Z-
dc.date.available2018-11-24T06:16:00Z-
dc.date.issued2008
dc.identifier.issn1475-2840
dc.identifier.urihttp://hdl.handle.net/10553/49324-
dc.description.abstractBackground: Thiazolidinediones exert anti-inflammatory and anti-oxidative roles and attenuate atherosclerosis by mechanisms partially independent of their metabolizing actions. High doses of angiotensin type I receptor (AT(1)R) blocker losartan (LST) seem to promote fat cell formation by preserving PPAR gamma activity.Methods: C57BL/ 6J diet-induced atherosclerotic susceptible mice randomly received a normal or a high-fat high-cholesterol (HFHC) diet and were treated with rosiglitazone (RG), LST or a vehicle for 12 weeks.Results: HFHC was associated with increased PPAR gamma gene expression without an over regulation of PPAR. responsive genes, whereas RG and LST treatments were found to maintain PPAR gamma activity without resulting in increased PPAR gamma gene expression. A better anti-inflammatory and antioxidant profile in mice treated with RG regarding LST was observed in spite of a similar PPAR gamma preserved activity. Chromatin immunoprecipitation (ChIP) assays revealed that animals under HFHC diet treated with RG showed a significant nuclear factor erythroid 2-like 2 (Nrf2)-dependent down-regulation of the expression of the CD36 gene.Conclusion: The PPAR gamma agonist RG exerts antioxidant properties that significantly reduced Nrf2-dependent CD-36 up-regulation in mice under HFHC diet. Because LST treatment was also associated with a preserved PPAR gamma activity, our data suggests that these RG antioxidant effects are partially independent of its PPAR gamma metabolizing properties.
dc.relation.ispartofCardiovascular Diabetology
dc.sourceCardiovascular diabetology,v. 7, p. 3
dc.subject.otherActivated-Receptor-Gamma
dc.subject.otherLow-Density-Lipoprotein
dc.subject.otherNitric-Oxide Synthase
dc.subject.otherSmooth-Muscle-Cells
dc.subject.otherPpar-Gamma
dc.subject.otherCardiovascular-Disease
dc.subject.otherOxidized Phospholipids
dc.subject.otherOxidative Stress
dc.subject.otherInhibits 3
dc.subject.otherMacrophages
dc.titleRosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeArticlees
dc.identifier.doi10.1186/1475-2840-7-3
dc.identifier.scopus41149089663
dc.identifier.isi000255912700001
dcterms.isPartOfCardiovascular Diabetology
dcterms.sourceCardiovascular Diabetology[ISSN 1475-2840],v. 7
dc.contributor.authorscopusid8758145300
dc.contributor.authorscopusid6603262370
dc.contributor.authorscopusid8311692000
dc.contributor.authorscopusid24829379200
dc.contributor.authorscopusid7005446255
dc.description.lastpage3
dc.description.firstpage3
dc.relation.volume7
dc.type2Artículoes
dc.identifier.wosWOS:000255912700001
dc.contributor.daisngid5660229
dc.contributor.daisngid1305938
dc.contributor.daisngid5867264
dc.contributor.daisngid2969359
dc.contributor.daisngid245684
dc.identifier.investigatorRIDC-1247-2010
dc.identifier.investigatorRIDD-2810-2013
dc.contributor.wosstandardWOS:Hernandez-Trujillo, Y
dc.contributor.wosstandardWOS:Rodriguez-Esparragon, F
dc.contributor.wosstandardWOS:Macias-Reyes, A
dc.contributor.wosstandardWOS:Caballero-Hidalgo, A
dc.contributor.wosstandardWOS:Rodriguez-Perez, JC
dc.date.coverdateFebrero 2008
dc.identifier.ulpgces
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptPatología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptCiencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0003-1663-3673-
crisitem.author.orcid0000-0003-0023-1063-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameRodríguez Esparragón, Francisco Javier-
crisitem.author.fullNameRodríguez Pérez, José Carlos-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

12
checked on Sep 19, 2021

WEB OF SCIENCETM
Citations

11
checked on Sep 19, 2021

Page view(s)

7
checked on Sep 18, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.